Sintilimab
Based on 3 publication(s) in Google Scholar
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer.
For research use only. We do not sell to patients.
- Purity: 99.1%
- CAS No.: 2072873-06-2
- Molecular Weight:144.04 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Sintilimab
More
Biological Activity
Human IgG4 kappa
Human
PDCD1/PD-1/CD279
Sintilimab (12 h) shows a high level of PD-1 occupancy and has superior T cell activating characteristics in human peripheral blood mononuclear cells (PBMCs)[2].
Sintilimab (0.16-100 nM; 5 days) induces high secretion levels of IFN-γ and IL-2 in primary T cell assays[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Sintilimab (1 mg/kg, 3 mg/kg and 10 mg/kg, s.c., a single dose) demonstrates a high affinity for PD-1 molecules in NCI-H292 tumor-bearing NOG mice[2].
Sintilimab (20 mg/kg, i.p., once interval 2 days for 21 days) combined with prebiotics inhibits the volume of transplanted tumors in lung adenocarcinoma and alleviates the liver and kidney injury[4].
Pharmacokinetic parameters of Sintilimab (10 mg/kg, i.v., a single dose) in hPD-1 knock-in mouse[2]
| Parameter | AUC0-4 (h·μg/mL) | AUCinf (h·μg/mL) | CL (mL/h) | Cmax (μg/mL) | T1/2 (h) | Vss (mL) |
| Sintilimab | 6597.888 | 7846.554 | 0.025 | 218.519 | 35.623 | 1.262 |